Key features and details | |
Cat. No. | MABL-1439 |
Name | Anti-DR5 mAbs |
Clone No. | AFD- TRA-8 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | theraputic, WB, ELISA, FC |
Species Reactivity | Human |
Basic Information | |
Specificity | The antibody is specific to human DR5 and does not bind other TRAIL receptors, other members of the TNF-receptor superfamily, or the murine homolog of DR5. |
Alternative Name | TRAILR2; TNFRSF10B; TRAIL receptor 2; tumor necrosis factor receptor superfamily member 10B |
UniProt | O14763 |
Immunogen | The antibody was raised by immunizing BALB/c mice with a fusion protein containing the extracellular portion of human DR5 and the Fc portion of human IgG1. |
Application Notes | The antibody has been characterised using Western blot and ELISA. It induces apoptosis in primary hepatocellular carcinoma cells and established liver cancer cell lines, but not normal human hepatocytes (Ichikawa et al., 2001). The antibody has been reported to function in flow cytometry to detect cell-surface expression of DR5 on Cos-7 cells transfected with full-length human DR5. This antibody has been demonstrated to have therapeutic benefits in the treatment of cancer in vivo and ex vivo (Buchsbaum et al., 2003; PMID: 14506165) (Straughn Jr et al., 2006; PMID: 16271751) (Estes et al., 2007; PMID: 17303227). |
Antibody First Published | Ichikawa et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nat Med. 2001 Aug;7(8):954-60. PMID:11479629 |
Note on publication | Describes the generation of the antibody, its characterisation and its function in triggering tumor apoptosis. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
